Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Short-term Investments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Short-term Investments for 6 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 63.86% to $61.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $61.9 million, a 63.86% decrease, with the full-year FY2025 number at $61.9 million, down 63.86% from a year prior.
  • Short-term Investments was $61.9 million for Q4 2025 at Lexicon Pharmaceuticals, down from $66.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $274.3 million in Q2 2024 to a low of $61.9 million in Q4 2025.
  • A 3-year average of $157.1 million and a median of $151.0 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: skyrocketed 224.14% in 2024, then tumbled 70.38% in 2025.
  • Lexicon Pharmaceuticals' Short-term Investments stood at $147.6 million in 2023, then rose by 16.09% to $171.3 million in 2024, then tumbled by 63.86% to $61.9 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Short-term Investments are $61.9 million (Q4 2025), $66.3 million (Q3 2025), and $117.6 million (Q2 2025).